Sign in
4

Changes in Ownership

Wave Life Sciences, Inc. Filed Acc 0001193125-25-314736

Chief Financial Officer sold 260,036 shares at an average $15.78 ($4,103,979)

  • Chief Financial Officer acquired 296,000 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Moran Kyle · Chief Financial Officer

Table I: Non-derivative

11 lines
Date Transaction Shares Price Value Owned after D/I
2025-12-08 Exercise or conversion : show line 1 in the form 10b5-1 +60,000 $2.83 $169,800 149,218 D
2025-12-08 Sale : show line 2 in the form 10b5-1 −60,000 $13.20 $792,000 89,218 D
2025-12-08 Exercise or conversion : show line 3 in the form 10b5-1 +100,000 $3.14 $314,000 189,218 D
2025-12-08 Sale : show line 4 in the form 10b5-1 −50,000 $15.00 $750,000 139,218 D
2025-12-08 Sale : show line 5 in the form 10b5-1 −50,000 $13.20 $660,000 89,218 D
2025-12-08 Exercise or conversion : show line 6 in the form 10b5-1 +50,000 $4.75 $237,500 139,218 D
2025-12-08 Sale : show line 7 in the form 10b5-1 −50,000 $18.00 $900,000 89,218 D
2025-12-09 Exercise or conversion : show line 8 in the form 10b5-1 +36,000 $8.17 $294,120 125,218 D
Open-market sales · 260,036 sh · avg $15.78 · $4,103,979

Table II: Derivative

5 lines
Date Transaction Shares Owned after D/I
2025-12-08 Grant or award : show line 12 in the form 10b5-1 Share Option (right to buy) −60,000 0 D
2025-12-08 Grant or award : show line 13 in the form 10b5-1 Share Option (right to buy) −100,000 75,000 D
2025-12-08 Grant or award : show line 14 in the form 10b5-1 Share Option (right to buy) −50,000 222,700 D
2025-12-09 Grant or award : show line 15 in the form 10b5-1 Share Option (right to buy) −36,000 0 D
2025-12-09 Grant or award : show line 16 in the form 10b5-1 Share Option (right to buy) −50,000 0 D
Loading xslF345X05/ownership.xml…